A new review in Advanced Cancer Research details how post-translational modifications regulate KRAS localization, activity, ...

A preclinical study shows that combining KRASG12D inhibition with CTLA-4 blockade dismantles a TGF-beta-driven regulatory T ...

Revolution Medicines’ stock slid 6.3% Thursday after newly released FDA review documents sparked investor unease around ...

PMV Pharmaceuticals is rated Buy, targeting $3–$4/share, driven by Rezatapopt's 46% response rate. Click to read more about ...

A new preclinical study reveals that KRAS-mutant gastric adenocarcinoma fosters a TGF-beta-dependent immunosuppressive tumour ...

New research reveals that chronic cigarette smoke exposure alters lung stem cells, driving mutations that result in distinct ...

Big pharma bets on KRAS G12D as oncology race intensifies Drugmakers chase tough G12D target with degraders and pan-KRAS ...

The KRAS G12D mutation, long considered "undruggable" for over 40 years, has emerged as a high-stakes battleground for global pharmaceutical ...

Fast track designation targets a post–immunotherapy and post-platinum KRAS G12C–mutant NSCLC population, enabling closer FDA ...

Penny Wagnon walks into a San Francisco conference room. Outside, a February cold snap sharpens the breeze off the Bay.

SK Biopharmaceuticals halts KRAS G12D program, pivots to RPT strategy in Korea Company pauses G12D inhibitor as KRAS race ...

Hello, I am Dr. Tansui.Recently, I have been receiving questions like this from patients researching pancreatic cancer ...